Novo Nordisk and Life Edit Therapeutics establish multi-targ

Novo Nordisk and Life Edit Therapeutics establish multi-target collaboration to discover and develop gene editing therapies for rare and cardiometabolic diseases

Novo Nordisk and Life Edit Therapeutics, Inc., an ElevateBio company focused on next-generation gene editing technologies and therapeutics, today announced a research and development collaboration to discover and develop gene editing therapies against a select set of therapeutic targets. With a focus on advancing ...

Related Keywords

Denmark , Marcus Schindler , Linkedin , Life Edit Therapeutics Inc , Novo Nordisk , Twitter , Life Edit , Life Edit Therapeutics , Mitchell Finer , Edit Therapeutics ,

© 2025 Vimarsana